5 Stocks The Best Performing Hedge Funds Are Piling Into

Loxo Oncology Inc (NASDAQ:LOXO) is yet another stock that made our list which is having a great 2017, gaining 33% so far this year. Casdin Capital was also high on this stock in the fourth quarter, adding 69,000 shares to its position, which contained 360,000 shares at the end of 2016. Opaleye Management also added 15,000 shares to its position, raising it to 125,000 shares.

Citi believes the run may be over for the stock for the time being however, as analyst Yigal Nochomovitz recently declared it to be fairly valued and downgraded it to ‘Neutral’ from ‘Buy’. Loxo Oncology Inc (NASDAQ:LOXO) is focused on targeting cancers which are caused by a genetic defect in a single gene, which it believes will give its treatments the best chance for success and to achieve best-in-class status compared to other treatment options. LOXO-101 and LOXO-195 are TRK inhibitors which have shown promising results, while LOXO-292 is an RET inhibitor.

Copyright: bialasiewicz / 123RF Stock Photo